GTH | Jotup

Gathid Sets New Identity and Access Governance Standard with Introduction of Patented Identity Model

Retrieved on:

Wednesday, April 10, 2024

Data Management, Security, Technology, Software, Networks, Internet, ROI, KPMG, AISA, UAR, ASX, GTH, Automation, PACS, RBAC, IAM, Kiosk, Sod, Data analysis, Memory, Algorithm, Organization, Online shopping

Inspired by the power of gathered identities, the platform pinpoints identity and access anomalies with its patented directed graph model.

Key Points:

Inspired by the power of gathered identities, the platform pinpoints identity and access anomalies with its patented directed graph model.
In Q4 2023, Gathid successfully transitioned from physical security to identity governance to address this gap.
Identity graph technology: Gathid’s patented approach constructs a daily identity graph model, enabling the representation of virtual data relationships between identities and access rights to systems.
The Gathid Graph does not attempt to maintain concurrency of its identity model; it simply receives daily snapshots and rebuilds the identity and access model, archiving the previous model when a new model is created from fresh data.

Genetron Health Announces Completion of Going Private Transaction

Retrieved on:

Thursday, March 28, 2024

Slate, Bank, GTH, Letter, Form 6-K, Committee, Form, Share, LLP, ADS, Security (finance), Consortium, Parent, King & Wood Mallesons, BNY Mellon

As a result of the Merger, the Company has become a wholly owned subsidiary of Parent and will cease to be a publicly traded company.

Key Points:

As a result of the Merger, the Company has become a wholly owned subsidiary of Parent and will cease to be a publicly traded company.
The deregistration will become effective 90 days after the filing of the Form 25 or such shorter period as may be determined by the SEC.
The Company intends to suspend its reporting obligations under the Securities Exchange Act of 1934, as amended, by filing a Form 15 with the SEC in approximately ten days following the filing of the Form 25.
Skadden, Arps, Slate, Meagher & Flom LLP is serving as U.S. legal counsel to the investor consortium (the “Consortium”), and King & Wood Mallesons is serving as PRC legal counsel to the Consortium.

Genetron Health Announces Shareholders’ Approval of Merger Agreement

Retrieved on:

Wednesday, February 21, 2024

Cayman Islands, Registrar, Proxy, Companies Act, Mergers and acquisitions, GTH, EGM, Sub, Security (finance)

Of the ordinary shares voted at the EGM, approximately 99.9% voted in favor of the proposal to authorize and approve the Merger Agreement, the Plan of Merger and the transactions contemplated thereby, including the Merger.

Key Points:

Of the ordinary shares voted at the EGM, approximately 99.9% voted in favor of the proposal to authorize and approve the Merger Agreement, the Plan of Merger and the transactions contemplated thereby, including the Merger.
The Merger Agreement, the Plan of Merger and the transactions contemplated thereby, including the Merger, were therefore duly authorized and approved by way of special resolutions as required by, and in compliance with, the Companies Act of the Cayman Islands.
Completion of the Merger is subject to the satisfaction or waiver of the conditions set forth in the Merger Agreement.
The Company will work with the other parties to the Merger Agreement towards satisfying all other conditions precedent to the Merger set forth in the Merger Agreement and completing the Merger as quickly as possible.

Genetron Health to Hold Extraordinary General Meeting of Shareholders

Retrieved on:

Wednesday, January 17, 2024

GTH, BNY Mellon, Registrar, Person, Bank, EGM, Schedule, Cayman Islands, Plan, ADS, Sub, Security (finance)

Shareholders of record as of 5 p.m. New York City time on February 9, 2024 will be entitled to attend and vote at the EGM and any adjournment thereof.

Key Points:

Shareholders of record as of 5 p.m. New York City time on February 9, 2024 will be entitled to attend and vote at the EGM and any adjournment thereof.
Requests for additional copies of the definitive proxy statement should be directed to the Company’s Investor Relations Department by email at [email protected].
The Company and certain of its directors and executive officers may, under SEC rules, be deemed to be “participants” in the solicitation of proxies from the shareholders with respect to the proposed Merger.
Further information regarding persons who may be deemed participants, including any direct or indirect interests they may have, is also set forth in the definitive proxy statement.

Genetron Health Enters into Definitive Merger Agreement for Going Private Transaction

Retrieved on:

Wednesday, October 11, 2023

BEIJING, Oct. 11, 2023 (GLOBE NEWSWIRE) -- Genetron Holdings Limited (“Genetron Health” or the “Company”, NASDAQ: GTH), a leading precision oncology platform company in China that specializes in offering molecular profiling tests, early cancer screening products and companion diagnostics development, announced today that it has entered into a definitive Agreement and Plan of Merger (the “Merger Agreement”) with New Genetron Holding Limited (“Parent”) and Genetron New Co Limited (“Merger Sub”), a wholly-owned subsidiary of Parent.

Key Points:

BEIJING, Oct. 11, 2023 (GLOBE NEWSWIRE) -- Genetron Holdings Limited (“Genetron Health” or the “Company”, NASDAQ: GTH), a leading precision oncology platform company in China that specializes in offering molecular profiling tests, early cancer screening products and companion diagnostics development, announced today that it has entered into a definitive Agreement and Plan of Merger (the “Merger Agreement”) with New Genetron Holding Limited (“Parent”) and Genetron New Co Limited (“Merger Sub”), a wholly-owned subsidiary of Parent.
The Board, acting upon the unanimous recommendation of a committee of independent and disinterested directors established by the Board (the “Special Committee”), approved the Merger Agreement and the Merger and resolved to recommend the Company’s shareholders vote to authorize and approve the Merger Agreement and the Merger.
The Special Committee negotiated the terms of the Merger Agreement with the assistance of its financial and legal advisors.
In connection with the Merger, the Company will prepare and mail to its shareholders a proxy statement that will include a copy of the Merger Agreement.

Genetron Health Announces Receipt of Notification from Nasdaq

Retrieved on:

Tuesday, May 23, 2023

GTH, Calendar, Auction

The Nasdaq notification letter has no current effect on the listing or trading of the Company’s securities on Nasdaq.

Key Points:

The Nasdaq notification letter has no current effect on the listing or trading of the Company’s securities on Nasdaq.
Pursuant to the Nasdaq Listing Rules 5810(c)(3)(A), the Company is provided with a compliance period of 180 calendar days, or until November 13, 2023, to regain compliance under the Nasdaq Listing Rules.
In the event the Company does not regain compliance by November 13, 2023, subject to the determination by the staff of Nasdaq, the Company may be eligible for an additional 180-day compliance period.
The Company’s business operations are not affected by the Nasdaq notification letter.

Cboe Global Markets Reports Trading Volume for January 2023

Retrieved on:

Friday, February 3, 2023

LIS, SPX, RUT, GTH, Acquisition, NEO, ADV, Cryptocurrency, Security (finance)

A total of 291.8 million contracts traded across all four Cboe U.S. options exchanges in January 2023.

Key Points:

A total of 291.8 million contracts traded across all four Cboe U.S. options exchanges in January 2023.
SPX options volume during Global Trading Hours (GTH) posted the second-best month ever in January with an ADV of 58,000 contracts – 55 percent above 2022 levels.
Total volume in Cboe Volatility Index® (VIX®) options was 11.4 million contracts, with an ADV of 571,000 contracts, up 10 percent from December 2022.
Cboe Europe Derivatives traded 3,824 contracts, a record monthly figure and beating the previous high of 3,647 contracts in December 2022.

Cboe Global Markets Reports Trading Volume for January 2023

Retrieved on:

Friday, February 3, 2023

LIS, SPX, RUT, GTH, Acquisition, NEO, ADV, Cryptocurrency, Security (finance)

A total of 291.8 million contracts traded across all four Cboe U.S. options exchanges in January 2023.

Key Points:

A total of 291.8 million contracts traded across all four Cboe U.S. options exchanges in January 2023.
SPX options volume during Global Trading Hours (GTH) posted the second-best month ever in January with an ADV of 58,000 contracts – 55 percent above 2022 levels.
Total volume in Cboe Volatility Index® (VIX®) options was 11.4 million contracts, with an ADV of 571,000 contracts, up 10 percent from December 2022.
Cboe Europe Derivatives traded 3,824 contracts, a record monthly figure and beating the previous high of 3,647 contracts in December 2022.

Genetron Health Regains Compliance With Nasdaq Minimum Bid Price Requirement

Retrieved on:

Wednesday, January 18, 2023

GTH, Auction

BEIJING, Jan. 18, 2023 (GLOBE NEWSWIRE) -- Genetron Holdings Limited ("Genetron Health" or the "Company", NASDAQ: GTH), a leading precision oncology platform company in China that specializes in offering molecular profiling tests, early cancer screening products and companion diagnostics development, today announced that the Company had received a notification letter (“Compliance Notice”) from the staff of the Listing Qualifications Department of the Nasdaq Stock Market LLC (“Nasdaq”), dated January 17, 2023, indicating that the Company has regained compliance with the minimum bid price requirement set forth under the Nasdaq Listing Rule 5450(a)(1) (the “Minimum Bid Price Requirement”).

Key Points:

BEIJING, Jan. 18, 2023 (GLOBE NEWSWIRE) -- Genetron Holdings Limited ("Genetron Health" or the "Company", NASDAQ: GTH), a leading precision oncology platform company in China that specializes in offering molecular profiling tests, early cancer screening products and companion diagnostics development, today announced that the Company had received a notification letter (“Compliance Notice”) from the staff of the Listing Qualifications Department of the Nasdaq Stock Market LLC (“Nasdaq”), dated January 17, 2023, indicating that the Company has regained compliance with the minimum bid price requirement set forth under the Nasdaq Listing Rule 5450(a)(1) (the “Minimum Bid Price Requirement”).
As previously announced, the Company was notified by Nasdaq on October 28, 2022 that the Company was not in compliance with the Minimum Bid Price Requirement as the bid price of the Company’s American depositary shares (“ADSs”) closed below US$1.00 per share for 30 consecutive business days.
On January 17, 2023, Nasdaq confirmed in the Compliance Notice that for the ten consecutive business days, from December 29, 2022 to January 13, 2023, the closing bid price of the Company’s ADSs has been at US$1.00 per share or greater.
Accordingly, the Company has regained compliance with Listing Rule 5450(a)(1), and the matter is closed.

Genetron Health Announces Receipt of Notification from Nasdaq

Retrieved on:

Monday, November 7, 2022

Annual report, Company, GTH, Compliance, GLOBE, Private Securities Litigation Reform Act, Securities Exchange Act of 1934, Terminology, COVID-19, Forward-looking statement, Molecular biology, NASDAQ, Calendar, SEC, Diagnosis, Auction, Audit, Nasdaq

The Nasdaq notification letter has no current effect on the listing or trading of the Companys securities on Nasdaq.

Key Points:

The Nasdaq notification letter has no current effect on the listing or trading of the Companys securities on Nasdaq.
The Companys business operations are not affected by the Nasdaq notification letter.
Genetron Holdings Limited ("Genetron Health" or the "Company") (Nasdaq: GTH) is a leading precision oncology platform company in China that specializes in cancer molecular profiling and harnesses advanced technologies in molecular biology and data science to transform cancer treatment.
Genetron Health also partners with global biopharmaceutical companies and offers customized services and products.